Ironwood Pharma

Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ironwood Pharma excels in Q4 with LINZESS growth and pipeline advancements

Ironwood Pharmaceuticals delivered a strong performance in Q4 2022, driven by LINZESS's growth and pipeline progress. Strategic priorities emphasize profitability and portfolio strength, while challenges around pricing and data release plans require attention. Opportunities exist in expanding LINZESS sales, pediatric indications, and pipeline investments for future growth.

Ironwood Pharma excels in Q1 with LINZESS driving growth

Ironwood Pharma's Q1 2023 showcased strong LINZESS demand, revenue growth, and profitability. The company's strategic focus on LINZESS and innovative pipeline positions it well for sustained success amidst market challenges and growth opportunities.

Ironwood Pharma reports strong Q2 performance and growth opportunities

Ironwood Pharmaceuticals showcased strong performance in Q2 2023, driven by robust U.S. net sales and strategic acquisitions.
While facing challenges in managing the impact of the VectivBio acquisition on EBITDA, the company is well-positioned for growth.
Opportunities lie in expanding LINZESS sales, advancing pipeline candidates like apraglutide, and diversifying into new indications.
Overall, Ironwood's focus on maximizing key products, pipeline advancement, and financial management sets a positive trajectory.

Ironwood Pharma reports strong Q3 performance amidst strategic acquisitions

Ironwood Pharmaceuticals showcased strong performance driven by LINZESS and the acquisition of VectivBio for apraglutide.
While facing challenges in managing financial losses and addressing competitive pressures, Ironwood remains focused on growth opportunities and product development.
Opportunities lie in upcoming Phase III data for apraglutide, pediatric market expansion for LINZESS, and exploring new patient subgroups for apraglutide.

Ironwood Pharma excels in Q4, eyes pediatric market growth

Ironwood Pharmaceuticals showcased robust financial performance, strategic acquisitions, and a focus on pipeline assets during their Q4 2023 earnings call. While facing challenges in defining efficacy and pricing strategies, the company remains optimistic about growth opportunities in the GI market, particularly in the pediatric segment.

Ironwood Pharma reports Q1 growth, prepares for apraglutide launch

Ironwood Pharma's Q1 2024 performance reflects growth in LINZESS prescription volume and positive developments in its pipeline, despite challenges in net sales and guidance adjustments. The company's strategic focus on maximizing LINZESS and preparing for apraglutide's launch presents opportunities for future growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Ironwood (IRWD) delivered earnings and revenue surprises of -62.50% and -17.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates

Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Ironwood Pharmaceuticals' Linzess sales are rising and pipeline candidates are progressing well. The company completes separation of its sGC business.

Will Ironwood Suffer From Dependence on Linzess' Progress?

News for Ironwood Pharma Stock (IRWD)